Cannabidiphorol (CBDP) acts as a negative allosteric modulator at two distinct sites of cannabinoid receptor 1.

Recent research demonstrates that cannabidiphorol (CBDP) acts as a negative allosteric modulator at CB1 receptors through a novel dual-site mechanism. This finding suggests CBDP could potentially provide therapeutic cannabinoid system modulation without psychoactive effects, though clinical applications remain theoretical. The study represents important mechanistic research that expands our understanding of cannabinoid receptor pharmacology.

Read More

Regulatory Digest 2026-03-07

✦ New Regulatory updates (digest-only, lower relevance) (57) [regulations.gov] Importer of Controlled-Bright Green(2024-20083)DEA1426 (57) [regulations.gov] Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429 (57) [regulations.gov] Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425 (57) [regulations.gov] Importer Controlled-VA Cooperative (2024-11795) DEA1374 (57)...

Read More